• Explore /
  • Poster
  • / Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): The CheckMate 040 study.

Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): The CheckMate 040 study.

Abstract Poster

Authors

null

Ignacio Melero

Clinica Universidad de Navarra, Pamplona, Spain

Ignacio Melero , Bruno Sangro , Thomas Cheung Yau , Chiun Hsu , Masatoshi Kudo , Todd S. Crocenzi , Tae-You Kim , SuPin Choo , Jorg Trojan , Tim Meyer , Theodore Hobart Welling III, Winnie Yeo , Akhil Chopra , Jeffrey Anderson , Christine Marie Dela Cruz , Lixin Lang , Jaclyn Neely , Hao Tang , Anthony El-Khoueiry

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT01658878

Citation

J Clin Oncol 35, 2017 (suppl 4S; abstract 226)

DOI

10.1200/JCO.2017.35.4_suppl.226

Abstract #

226

Poster Bd #

A4

Abstract Disclosures

Similar Posters

Poster

2019 Gastrointestinal Cancers Symposium

Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.

Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.

First Author: Masatoshi Kudo

First Author: Todd S. Crocenzi

First Author: Aiwu Ruth He

First Author: Bruno Sangro